# Swiss Life Sciences Trend Analysis 2017

THE LATEST FIGURES ON THE SWISS LIFE SCIENCES & BIOTECHNOLOGY INDUSTRY BROUGHT TO YOU BY C5 COMMUNICATIONS AND BIOTECHGATE



## Swiss Life Sciences Trend Analysis 2017

SOURCE: biotechgate.com

The "Swiss Life Sciences Trend Analysis" is based on data entered in the Biotechgate Database available at www.biotechgate.com.

The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

Switzerland holds only 0.1% of the world's population, but it remains a leader in wealth, exports and life sciences.

As a smaller country, Switzerland frequently looks beyond its borders, **building strong** international relationships and focusing heavily on exports.

Currently its **largest export sector is chemical, pharmaceuticals and biotech**, accounting for 41% of total Swiss exports.

Switzerland also houses several large multinational corporations, such as Nestle, Novartis and Sygenta, who use the region as a hub for their global networks of R&D collaborations and manufacturing.

The Swiss growth strategy is largely underpinned by an emphasis on **constant innovation** and **internationalism**. A key focus is given to **collaboration with foreign researchers** and also to facilitating **growth in developing and transitioning countries**.





#### Swiss Life Sciences Trend Analysis 2017

| Content  |    |
|--|----|
| Overview of the Swiss Industry                               | 4  |
| Life Sciences & Biotechnology Industry - Overview            | 5  |
| Life Sciences & Biotechnology Industry - Number of Employees | 6  |
| Life Sciences & Biotechnology Industry - Company Ownership   | 7  |
| Biotech Companies - Foundation Timeline                      | 8  |
| Biotechnology Companies -Key Activities                      | 9  |
| Biotech products - Breakdown by Indication                   | 10 |
| Biotech products - Pipeline                                  | 11 |
| Biotechnology Financing in Switzerland – 5 year report       | 12 |
| Major Biotech Venture Financing Rounds in 2016               | 13 |





#### Overview

#### Life Science Industry

| April 2017 Statistics                                  |                |
|--|----------------|
| Total Biotech Companies                                | 430            |
| Medtech companies                                      | 232            |
| Pharma companies                                       | 70             |
| Investor companies                                     | 44             |
| Public / Non-Profit Organizations / Medical Facilities | 211            |
| Other life science related companies                   | 1060           |
| Percentage of Publicly Owned Companies                 | 1.8%           |
| Biotech Venture financing 2015 / 2016                  | USD 409m/USD   |
|  | 370m           |
| Life Sciences Venture Financing 2015 / 2016            | USD 782m / USD |
|  | 458m           |
| Number of Technologies                                 | 201            |
| Licensing Opportunities                                | 92             |

#### **Biotechnology Industry**


| 2017 Statistics                        |            |
|--|------------|
| Total Biotech companies                | 430        |
| Biotech – Therapeutics and Diagnostics | 144        |
| Biotech – R&D Services                 | 208        |
| Biotech - Other                        | 78         |
| Percentage of SMEs                     | 78%        |
| Percentage of publicly owned companies | 2%         |
| Biotech venture financing 2015/2016    | USD 409m / |
|  | USD 370m   |
| Licensing opportunities                | 79         |






#### Number of Employees

#### LIFE SCIENCES



#### **BIOTECH**









#### Company Ownership

#### LIFE SCIENCES

Publicly listed on stock exchange 3.7%




#### **BIOTECH**








#### Biotech Companies - Foundation Timeline







#### Biotechnology Companies - Key Activities








#### Biotech products - Pipeline

#### NUMBER OF BIOTECH PRODUCTS IN DEVELOPMENT







#### Biotechnology Financing – 5 year report







### Discover The Latest European Developments In Life Sciences IP

On the 11<sup>th</sup> and 12th of October, C5 will be hosting the Life Sciences IP Summit in Munich, Germany.

Join us for the fourth year of this leading conference to discover:

- Pharmaceutical lifecycle management strategies
- How to protect your patent portfolio using Preliminary Injunctions
- Best practices for effective Cross Border Litigation
- How to navigate the CRISPR patent landscape ...and many more exciting topics delivered by industry experts





Join us to gain practical insights from industry experts on how to maximise the value of your Pharma and Biotech IP, manage changing regulations and innovate in new markets!

**Download the DRAFT AGENDA by clicking here!** 

**Book your place TODAY at the cheapest price!** 

